Vet-LIRN antimicrobial resistance surveillance through collection of AMR data and whole genome sequencing of isolates from Canadian provinces

Vet-LIRN 通过收集 AMR 数据和加拿大各省分离株的全基因组测序进行抗生素耐药性监测

• 批准号: 10468714
• 负责人: Durda Slavic
• 金额: $ 9.78万
• 依托单位: UNIVERSITY OF GUELPH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-20 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10468714
• 关键词: Vet; LIRN; antimicrobial; resistance; surveillance

Project Summary/Abstract As a part of the FDA Veterinary Laboratory Information Response Network (Vet-LIRN) initiative ‘to support enhanced human and animal food safety’ Animal Health Laboratory (AHL) acquired MiSeq Illumina and was tasked to established a Canadian veterinary diagnostics laboratory unit (5 source labs and 1 WGS regional lab) to support and expand Vet-LIRN's Antimicrobial Resistance-Whole Genome Sequencing (AMR-WGS) program. This unit was established in 2018 and the program ran throughout 2019 with bacterial isolates (604), metadata and antimicrobial susceptibility results collection and whole genome sequencing (WGS) of selected isolates (270). The isolate collection slowed down in the second quarter of 2020 because of COVID-19, and also one laboratory dropped out of the program due to a staffing shortage. As a result, our objectives for this multiyear project are: 1. To recruit another source laboratory for isolate, metadata and antimicrobial susceptibility results collection for 2021. 2. To continue established collaboration with other source laboratories by providing them with supplies and covering quarterly shipping expenses for isolates and data collection. 3. To continue with isolates collection at AHL. 4. To increase surge capacity and capability of AHL in order to aid Vet-LIRN AMR surveillance efforts and clinical disease investigations using harmonized methodology by: a. Using Illumina MiSeq to do WGS of bacterial isolates following protocols provided by Vet-LIRN. b. Participating in proficiency testing provided by GenomeTrakr. c. Submitting sequence information to NCBI to make them publicly available.

项目概要/摘要 作为 FDA 兽医实验室信息响应网络 (Vet-LIRN) 计划的一部分 “支持增强人类和动物食品安全”动物健康实验室 (AHL) 收购 MiSeq Illumina 并受命建立加拿大兽医诊断实验室单位 （5 个源实验室和 1 个 WGS 区域实验室）支持和扩展 Vet-LIRN 的抗菌药物 耐药性全基因组测序 (AMR-WGS) 计划。本单位成立于 2018 年，该计划贯穿 2019 年，涉及细菌分离株 (604)、元数据和 选定的抗菌药物敏感性结果收集和全基因组测序（WGS） 分离物（270）。 2020 年第二季度分离物收集速度放缓，原因是 由于人员短缺，COVID-19 以及一个实验室退出了该计划。作为一个 因此，我们这个多年项目的目标是： 1. 招募另一个来源实验室进行分离物、元数据和抗菌药物敏感性 2021 年结果收集。 2. 继续与其他来源实验室建立合作关系，提供 提供物资并支付用于分离物和数据收集的季度运输费用。 3. 继续在 AHL 进行分离株收集。 4. 提高 AHL 的激增能力和能力，以协助 Vet-LIRN AMR 使用统一方法进行监测工作和临床疾病调查 经过： 一个。使用 Illumina MiSeq 按照实验方案对细菌分离株进行全基因组测序 (WGS) 由 Vet-LIRN 提供。 b.参加 GenomeTrakr 提供的能力验证。 c.向 NCBI 提交序列信息以使其公开。